Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB-7342 in obesity and overweight
NCT07324850Phase 1Not yet recruiting
- Sponsor
- SanegeneBio
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Peptides
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing SGB-7342 with Placebo (2 arms). Primary endpoint: Adverse Events at 6 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
SGB-7342
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07324850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324850.